RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.21
+7.60%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -47.2%
- EBIT
- -50.9%
- EPS
- -87.5%
- Free cash flow
- -26.4%
- Operating cash flow
- -26.9%
Forward estimates
Based on analyst estimates
- Revenue
- -99.6%
- EBITDA
- +62.4%
- EPS
- -64.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -50.9%
- EBIT
- -50.6%
- Net income
- -42.4%
- EPS
- +24.3%
- Free cash flow
- -31.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026